
    
      This is a dose escalation study, which means that the first group of patients will receive a
      low dose of PS-341 (VELCADE) and Docetaxel (Taxotere). If the low dose of VELCADE and
      Taxotere appears to be safe, then the next group of patients will receive a higher dose of
      VELCADE and Taxotere.
    
  